Long-Term Data Support BCT for BRCA-Mutated Breast Cancer
-
By
May 16, 2025
-
2 min
-
1
South Korean study investigated oncologic outcomes of BCT vs. mastectomy in breast cancer patients with BRCA1 or BRCA2 pathogenic variants.
-
2
Included 575 female patients with a median follow-up of 8.3 years.
-
3
No significant differences in oncologic outcomes between BCT and mastectomy groups.
-
4
BCT considered a safe and effective option, offering comparable long-term outcomes to mastectomy.
-
5
Further prospective studies recommended for confirmation of findings.
-
Researchers from South Korea investigated the long-term oncologic outcomes of breast-conserving treatment (BCT) compared with mastectomy in patients with breast cancer carrying BRCA1 or BRCA2 pathogenic variants. The study included 575 South Korean female patients with a median follow-up of 8.3 years. The results, published in JAMA Network Open, indicated that there were no significant differences in oncologic outcomes between the BCT and mastectomy groups, suggesting that BCT is a safe and effective surgical option for these patients, offering comparable long-term oncologic outcomes to mastectomy.
-
1
South Korean study investigated oncologic outcomes of BCT vs. mastectomy in breast cancer patients with BRCA1 or BRCA2 pathogenic variants.
-
2
Included 575 female patients with a median follow-up of 8.3 years.
-
3
No significant differences in oncologic outcomes between BCT and mastectomy groups.
-
4
BCT considered a safe and effective option, offering comparable long-term outcomes to mastectomy.
-
5
Further prospective studies recommended for confirmation of findings.
Listen Tab content
